Style Editor Docs
     
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • US FDA IDE Process Updates
    • Human Clinical Trials
  • IsoPet®
    • IsoPet® Therapy
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • Our MIssion with IsoPet®
    • Animal Studies
      • Canine Studies
      • Feline Studies
  • About
    • Management & Consultants
    • Advisory Boards
  • Contact
  • Investors
    • Board of Directors
 (+1) 509‑736-4000,  
   Contact Us
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • US FDA IDE Process Updates
    • Human Clinical Trials
  • IsoPet®
    • IsoPet® Therapy
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • Our MIssion with IsoPet®
    • Animal Studies
      • Canine Studies
      • Feline Studies
  • About
    • Management & Consultants
    • Advisory Boards
  • Contact
  • Investors
    • Board of Directors
  1. About

Awards & Recognition - Vivos Inc. has been recognized as a leader by local, state and federal agencies.

 

• $1.3 million U.S. Federal grant for brachytherapy 

• Leaders in Healthcare Award, Seattle Business Magazine

• Federal Laboratory Consortium Award for Excellence in Technology Transfer, 

   a prestigious honor recognized by the US Secretary of Energy and US Senator Murray

 

August 3, 2013 - The Secretary of Energy, Washington, D.C.

Download
Secretary of Energy 2013 Award for Excellence in Technology Transfer
DOE Award of Excellence in Technology.pd
Adobe Acrobat Document 324.1 KB
Download

Home Page Cover Image: 

 

Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.

 

Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.

RadioGel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® Therapy Application(s)


Precision Radionuclide Therapy (PRnT)


Vivos Inc.
 - (OTCQB:RDGL) Investor Relations 

Contact

 

Main colors
   bg-primary
   bg-primary-light
   bg-primary-dark
   bg-secondary
   bg-secondary-dark
Template sections
   body
   top-header
   header
   content
Footer Styles
   background
   text color
   link color
   horizontal line
Buttons
   style 1
   style 2
   style 3
Other elements
  social icons
  navigation color
  subnav background
Mobile navigation
   background color
   navigation color
Template configurations
has-right-nav g-font
navigation styles
size-15 weight-400 snip-nav
content styles
form-white
footer styles
o-form color-white
Typography
Heading H1
weight-600
Heading H2
weight-600
Heading H3
weight-600
Buttons
weight-600 is-uppercase
Animations

Note:
All changes made here will be applied to your entire website.
is-switcher admin-only

draggable-logo

About | Privacy Policy | Cookie Policy | Sitemap
© 2022 Vivos Inc. | RadioGel™ is a registered trademark | IsoPet® is a registered trademark
Log out | Edit
  • Management & Consultants
  • Advisory Boards
  • Scroll to top